News Hub | News Direct

Doceree Secures Patent for its Groundbreaking Technology Empowering Marketers to Elevate Patient-Physician Engagement Through Real-Time Triggers on EHR Platforms

Doceree

Doceree, the leading global healthcare marketing platform building unprecedented solutions for programmatic HCP marketing using proprietary data tools, today announced the grant of a patent by US Patent and Trademark Office (USPTO) for its distinguished feature ‘Triggers’ that uses clinical data as real-time prompts for messaging to HCPs on Electronic Health Record Platforms, in a HIPAA-compliant and privacy-forward way. In the United States, physicians possess the potential to enhance healthcare delivery by leveraging relevant information; however, the challenge lies in the timely accessibility of crucial data. Despite the ongoing digital transformation in the healthcare sector, Healthcare Professionals (HCPs) continue to face a notable gap in accessing up-to-date information, a resource that is currently exclusive to life sciences organizations. As the industry undergoes rapid digitization, the need for efficient information dissemination to empower healthcare providers becomes increasingly evident. Bridging this information gap, Doceree introduced Triggers- a technological solution designed to guarantee the delivery of optimal and well-informed care to patients. Doceree's groundbreaking patent, officially paves the way for the integration of Doceree Triggers into the pharmaceutical marketing landscape. This patent encompasses a sophisticated medical product processing system that employs a first graphical user interface connected to an Electronic Health Record (EHR) platform. The system is designed to display messages in real-time to medical providers, tailored to their patients' predefined conditions. These conditions are inputted into the patient's electronic health record during the interaction between the patient and the healthcare provider, encompassing crucial details such as definitions of international classifications of diseases (ICD) codes. This patent not only represents a pivotal achievement, affirming Doceree's pioneering strategy in revolutionizing the interaction between pharmaceutical marketing and healthcare professionals, but it also plays a crucial role in aiding Electronic Health Record (EHR) platforms. The patent ensures real-time clinical data mapping in a HIPAA-compliant manner, contributing to the optimization of EHRs for health data interoperability. This optimization holds significant importance in supporting clinical research efforts. The seamless integration of research and clinical care within a health system has the potential to boost clinical trial participation rates, enhance health outcomes, reduce the cost of care, and foster greater patient satisfaction. " This patent not only signifies our steadfast dedication to pushing the boundaries and creating pioneering solutions for addressing the industry's most intricate challenges but also stands as a significant milestone in our journey towards establishing leadership in healthcare innovation and technology," stated Harshit Jain MD, Founder, and Global CEO of Doceree. " Beyond its legal implications, this inaugural patent reflects the resilience and forward-thinking ethos that defines our company. It serves as the bedrock for sustained success in the ever-evolving landscape of innovation, embodying our commitment to continuous advancement. The issuance of this patent is a powerful reminder of what can be achieved through collaborative efforts and a shared dedication to our strategic objectives," he emphasized. Doceree Triggers stands out by offering pharmaceutical manufacturers a distinctive set of capabilities. It enables the strategic planning and coordination of healthcare provider and direct-to-consumer campaigns, leveraging comprehensive insights into patient and provider behaviors, including the evaluation of past and present script performance. The platform empowers users to activate media seamlessly across various channels, encompassing display, video, and connected TV, all while optimizing bids to enhance overall business outcomes. Real-time performance measurement is a key feature, providing immediate insights into each campaign's effectiveness. Moreover, Doceree Triggers facilitates the dynamic optimization of ongoing campaigns by automatically adjusting parameters, enhancing audience quality, boosting script lift, and maximizing overall media efficiency. This multifaceted approach ensures that pharmaceutical marketing efforts are not only well-informed but also agile and responsive, driving impactful results in the competitive landscape. About Doceree: Doceree is a global platform building unprecedented solutions for healthcare professional (HCP) messaging with proprietary data and advanced tools. Utilizing an extensive global network of digital endemic and point-of-care platforms, Doceree facilitates seamless and meaningful communication between life sciences brands and HCPs, ensuring delivery of highly personalized messages to HCPs at scale. To learn more, https://doceree.com/us/doceree-triggers/. Contact Details Doceree Priyanka Bhasin +91 78387 03702 priyanka.bhasin@doceree.com Doceree Tanya Singh +91 70420 89805 tanya.singh@doceree.com Company Website https://doceree.com/us/doceree-triggers/

February 06, 2024 09:00 AM Eastern Standard Time

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy

Benzinga

By Jeremy Golden, Benzinga A clinical-stage biotechnology company has published promising preclinical data in Cancer Immunology Research, a journal of the American Association for Cancer Research (AACR). The data produced by Elicio Therapeutics Inc. (NASDAQ: ELTX) demonstrates how Elicio’s proprietary Amphiphile (AMP) lymph node-targeting immunotherapy platform, carrying cognate peptide and adjuvant cargos, boosted T cell receptor-modified T cell (TCR-T cell) therapies while enhancing anti-tumor function and eradicating solid tumors. According to Peter DeMuth, Ph.D., Chief Scientific Officer at Elicio Therapeutics, optimization of TCR-T cell therapy could potentially have wide-ranging therapeutic benefits in many previously intractable solid tumors. During the study, AMP immunotherapy enhanced the infiltration and function of TCR-T cells in the tumor microenvironment and led to epitope spreading against diverse tumor targets. Additionally, long-term protection against tumor recurrence in AMP-treated mice was associated with antigen spreading to additional tumor-associated antigens not targeted by the treatment. “In this study, we’ve demonstrated that boosting TCR-T cell therapy directly in the lymph nodes with AMP immunotherapy resulted in durable anti-tumor T cell responses and tumor eradication,” DeMuth said. “The AMP treatment uniquely promoted potent mechanisms for immune activation in lymph nodes to invigorate both adoptive and endogenous anti-tumor T cell immunity. Simple application to a variety of cancer targets including mKRAS, HPV E7 and NY-ESO-1 could elevate existing TCR-T cell therapies to generate powerful new combinations for hard-to-treat solid tumors.” Elicio Therapeutics is developing a pipeline of novel immunotherapies for the treatment of cancer. Three vaccine candidates are currently in Elicio Therapeutics’ pipeline: ELI-002, ELI-007 and ELI-008. Elicio’s proprietary AMP platform delivers investigational immunotherapeutics directly to the lymph nodes, sometimes referred to as the “brain center” of the immune system. In previous Elicio studies, the results found that AMP immunotherapy promoted specific trafficking and retention of payloads into lymph nodes, yielding enhanced T cell numbers, persistence and functional quality. Preliminary phase 1 data from the ongoing study of Elicio’s lead asset, ELI-002, demonstrated significant T cell responses – including both CD4+ and CD8+ – when administered as an adjuvant monotherapy in patients with pancreatic and colorectal cancers. The strength of the T cell response induced by ELI-002, an mKRAS-specific AMP vaccine, was further correlated to significant improvements in tumor biomarker response, along with reduced risk of progression and death. This indicates an association between the ELI-002 mechanism of action and clinical outcome. “This study adds to our growing body of preclinical and clinical evidence demonstrating the importance of the lymph nodes and the robust efficacy that our AMP immunotherapy strategy can potentially achieve for patients with solid tumors, both as a monotherapy and in combination with other strategies,” said Robert Connelly, Chief Executive Officer at Elicio Therapeutics. “The AMP platform provides attractive potential for broad and rapid application to clinical and developmental TCR-T cell programs. We look forward to finding the right partner to advance this promising combination into the clinic for patients with solid tumors.” Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 06, 2024 08:35 AM Eastern Standard Time

Image

Exciting Transition as Executive Director Prepares for New Chapter

National Contract Management Association

The NCMA Contract Management Institute (CMI) announces that Soraya Correa, who has served as the dedicated Executive Director for the past year, will be joining the team at National Industries for the Blind as their new President and CEO-Elect. Ms. Correa will be transitioning into a governance role, maintaining a crucial connection with CMI and its strategic direction. This shift reflects her continued dedication to the institute's mission and the desire to contribute to its future success at a governance level. Kraig Conrad, CEO of NCMA and Chair of the CMI Governance Board, "We express our gratitude for the invaluable contributions Soraya has made to the relaunch of the Contract Management Institute. Her enduring legacy is marked by a steadfast commitment to remaining actively engaged in the NCMA community and continuing her involvement in the governance of CMI." Amid expressions of gratitude for her contributions, Ms. Correa reflected on her time at the Institute, underscoring the impact she has had on its relaunch, community engagement, and governance. “While I am excited about this new opportunity with the National Industries for the Blind (NIB), I am sad to leave CMI. As Executive Director of CMI I had the opportunity to work with the outstanding leadership, team, and members of NCMA, an experience I will always appreciate and remember fondly. I remain committed to the success of CMI and the vital role it plays in advancing the contract management profession. As I embark in my new role at NIB, I will continue to support NCMA initiatives, especially those of the CMI!” In the interim, taking over the Executive Director position for CMI will be Mr. Conrad. Stay tuned for more updates and CMI’s research projects begin this Spring. For inquiries and paper submissions, please contact info@ncmahq.org. The Contract Management Institute (CMI) is a leading professional organization dedicated to advancing the field of contract management. With a mission to drive innovation, promote excellence, and enhance the role of the contracting professional, CMI provides valuable resources including collaboration and partnership opportunities for individuals and organizations involved in contract management across government, industry, and academia. The Institute serves as a catalyst for the study of the profession to elevate engagement, standards, and professional development. The CMI mission and vision are aligned with its parent, NCMA. CMI is a 501(c)(3) charitable organization. The National Contract Management Association (NCMA) - www.ncmahq.org - stands as the premier contract management organization whose mission is to collaborate towards a globally recognized contract management profession that strengthens its nexus with related acquisition communities. Serving approximately 20,000 members in both the public and private sectors, NCMA propels the growth, advancement, and impact of practitioners through a steadfast commitment to serve through the open exchange of ideas in neutral forums. Contact Details NCMA Holly DeHesa +1 281-865-3296 holly.dehesa@ncmahq.org Company Website https://www.ncmahq.org

February 05, 2024 07:05 PM Eastern Standard Time

Clene Inc. announces positive results from CNM-Au8 results from MS trial

Clene Inc

Clene Inc (NASDAQ:CLNN) CEO Rob Etherington joined Steve Darling from Proactive to share news regarding the latest findings from the long-term open-label extension (LTE) of the VISIONARY-MS trial. This trial focuses on participants with stable relapsing multiple sclerosis (MS) and represents nearly three years of follow-up research. Following the conclusion of the double-blind period of the trial, participants were given the opportunity to continue with CNM-Au8® treatment at a dose of 30mg for an additional 96 weeks during the LTE phase. The analysis encompassed the modified intent-to-treat population, which included all study participants with valid clinical data. Etherington highlighted the key finding that long-term CNM-Au8 treatment showcased improvements in vision, as measured by low contrast visual acuity, an essential assessment of visual function in individuals living with multiple sclerosis. Remarkably, these improvements in vision persisted for 35 months from randomization, demonstrating the sustained efficacy of CNM-Au8 over an extended period. Moreover, the data revealed consistent and robust overall enhancements not only in vision but also in cognition among participants treated with CNM-Au8 for nearly three years from randomization. These results are particularly noteworthy for their potential to positively impact disease progression and potentially reverse established disability, representing a significant therapeutic breakthrough for patients with MS. Full clinical results from the long-term open-label extension will be officially presented at the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum, scheduled to take place from February 29 to March 2, 2024, in West Palm Beach, Florida. Clene's commitment to advancing treatments for multiple sclerosis is evident in these promising results, and their ongoing research holds great promise for enhancing the quality of life for individuals affected by this condition. The potential to offer effective long-term solutions and improve both vision and cognitive function is a significant step forward in the battle against multiple sclerosis. Contact Details Proactive Canada Proactive Canada +1 604-688-8158 action@proactiveinvestors.com

February 05, 2024 02:30 PM Eastern Standard Time

Video

LungLife AI announces success in Validation of LungLB in multi-site, prospective clinical study

LungLife AI Inc

LungLife AI CEO Dr. Paul Pagano joined Steve Darling from Proactive to discussed the groundbreaking lung cancer detection technology developed by the company. LungLife AI is dedicated to addressing the critical issue of early detection in lung cancer, which remains the leading cause of cancer-related deaths. Dr. Pagano highlighted the sobering statistic that 80% of lung cancer cases are detected too late, contributing to the high mortality rate associated with this disease. The company's lung lb test, which has recently undergone successful validation, is poised to revolutionize the early detection of lung cancer by addressing the challenge of evaluating small nodules under 15 millimetres in size. Early intervention is crucial in improving patient outcomes, and the lung lb test is designed to meet this unmet need. Physicians have expressed excitement about the potential of this test to transform the landscape of lung cancer detection. Unlike existing methods, the lung lb test takes a unique approach by examining circulating genetically abnormal cells in the blood. This innovative approach offers a complementary and highly sensitive means of detecting lung cancer, enhancing the chances of early intervention and improved patient prognosis. Dr. Pagano discussed the competitive landscape, emphasizing LungLife AI's patented methods and proprietary technologies that set their approach apart in the field of lung cancer detection. Looking ahead, LungLife AI plans a methodical introduction of the lung lb test through an early access program, ensuring a seamless transition into healthcare settings. The next six to twelve months will involve a commercial proof of concept, with the company collaborating with hospital sites and working towards securing coverage from insurance providers. The potential life-saving impact of LungLife AI's technology and their strategic approach to making it accessible to patients and healthcare providers mark a significant contribution to advancing the field of lung cancer detection. The company's dedication to improving early detection rates and ultimately reducing the mortality associated with this devastating disease underscores their commitment to patient care and well-being. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 05, 2024 02:25 PM Eastern Standard Time

Video

Flora Growth Corp's CEO Reveals Record-Breaking Financials and Exciting 2024 Plans

Flora Growth Corp

Flora Growth CEO Clifford Starke joined Steve Darling from Proactive to share exciting news about the company's remarkable financial performance and its strategic plans for the future. Flora Growth is a diversified company with three main pillars, and it recently reported its best-ever financial results. Starke highlighted Flora's three core pillars, Vessel which is a rapidly growing brand with widespread distribution, the CBD Gummy Division, and Fatima a pharmaceutical company based in South Germany. The company recently went under strategic restructuring, which included the sale of an unprofitable Colombian entity and streamlining its team, which led to a net income of $1.1 million in the last quarter. The success of the last quarter is attributed to these strategic decisions, setting the stage for a promising 2024. Looking ahead, Flora Growth plans to enter the rapidly growing US beverage market by launching a product called Mellow in Q1. Leveraging its strong distribution network, the company aims to capitalize on the untapped potential in the beverage segment. Starke emphasized the importance of continuous product innovation, hinting at upcoming releases in 2024 that will compete with established brands in the dry herb space. As Flora Growth anticipates a record-breaking year, Starke highlighted their commitment to product innovation and strategic expansion, positioning the company as one to watch in the cannabis industry. Contact Details Proactive United States Proactive United States +1 347-449-0879 action@proactiveinvestors.com

February 05, 2024 01:03 PM Eastern Standard Time

Video

22nd Century Group CEO Larry Firestone: Transforming Tobacco Industry with FDA-Approved VLN Brand

22nd Century Group Inc

22nd Century Group new CEO Larry Firestone joined Steve Darling from Proactive to discuss his role and the company's strategic direction. 22nd Century Group is an agricultural biotech firm specializing in tobacco harm reduction and developing low-nicotine content plants for cigarettes. Notably, the company received FDA authorization for modified risk tobacco products in December 2021, with its flagship brand, VLN (Very Low Nicotine), aimed at addressing smoking-related health issues. Firestone emphasized the strategic shift the company is undergoing, which includes streamlining operations, divesting non-core assets such as the hemp cannabis business, and refocusing solely on the tobacco sector. The company's primary goal for 2024 is achieving financial self-sustainability, with a focus on cost optimization, gross margin improvement, and streamlining the overhead structure. 22nd Century Group is also committed to expanding its presence in established markets, particularly in the United States, and delivering its core products. Firestone's leadership will play a crucial role in guiding the company through these transformative changes and positioning it for growth and success in the coming years. This strategic shift and renewed focus on tobacco harm reduction reflect 22nd Century Group's commitment to addressing health-related issues associated with smoking and its determination to make a positive impact in the tobacco industry. Contact Details Proactive United States Proactive United States +1 347-449-0879 action@proactiveinvestors.com

February 05, 2024 07:29 AM Eastern Standard Time

Video

2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge

Benzinga

By Faith Ashmore, Benzinga The global population is experiencing a scary increase in colorectal cancer, especially among young people. Colorectal cancer (CRC) diagnoses have been steadily rising since the 1990s; in 1995 the proportion of these cancer cases in adults younger than 55 was 11%, and in 2019, the number was 20%. It is recommended that adults start screening for colorectal cancer at age 45 but with the increase in prevalence, the value of early detection cannot be understated. While doctors still aren’t sure of the reason behind this increase, they are urging the public to take these numbers seriously and embrace preventative measures for early detection. Companies like Mainz Biomed (NASDAQ: MYNZ), a company that specializes in developing molecular genetic diagnostic solutions for life-threatening conditions, are leading the charge in helping make that happen. This company has created ColoAlert®, an innovative product that addresses the need for easier and more accessible cancer screenings for quick detection and treatment of colorectal cancer. The non-invasive and user-friendly test aims to make colorectal cancer screening fast, simple and precise. Once launched in the U.S. Mainz Biomed's ColoAlert will compete with Cologuard from Exact Sciences Corporation (NASDAQ: EXAS), a well-established company that commands a market cap of over $10 billion. The key difference between Cologuard and ColoAlert is that ColoAlert requires far less stool collection than its competitor, a testament to ColoAlert’s technology. This not only increases convenience for the patient but also cuts down on shipping costs and lab time. The only other detection model outside of a traditional colonoscopy is a blood-stool test; however, these tests can only detect cancer, not pre-cancerous polyps. Mainz Biomed has partnered with Liquid Biosciences to ensure its cutting-edge products are top-of-the-line. Recently, Mainz Biomed conducted a multi-center international clinical trial in Germany and Norway to evaluate the effectiveness of incorporating mRNA biomarkers into ColoAlert®. The study yielded impressive findings, demonstrating a high sensitivity of 94.4% and specificity of 97.5% for detecting CRC. Additionally, the screening test showed a sensitivity of 80% and specificity of 95.2% in detecting precursor lesions, including advanced adenomas that may develop into CRC. In other words, ColoAlert is designed to detect pre-cancerous polyps as well as identify individuals who have colorectal cancer. The CDC reports that colorectal cancer is the second most fatal cancer in the United States and Europe. However, it is also the most preventable, with early detection leading to survival rates above 90%. ColoAlert can be instrumental in preventive care for colorectal cancer. The company reports it has experienced success in Germany, where the product is available through labs, industry partnerships and online for purchase. In 2024, Mainz Biomed is looking to replicate this success in the U.S. and is planning to launch a pivotal trial, seeking FDA approval for its product. If successful, the company will look to partner with a network of labs across the country to increase accessibility to its product with the hope that more Americans will be able to detect pre-cancerous polyps before it is too late. With the American Cancer Society predicting over 600,000 cancer deaths and the equivalent of 5,000 cancer diagnoses each day in 2024, prevention is key to treatment. The preventive healthcare market has gotten a lot of attention in recent years, and it is expected to reach $415 billion by 2031 with a CAGR of 9.7% from 2024 to 2031. Mainz Biomed’s ColoAlert is a great example of the power of technology that can screen for pre-cancerous markers. Mainz Biomed's dedication to pushing the limits of diagnostic technology, enhancing accessibility and its growth trajectory potentially establish it as a formidable presence in the industry, setting it apart from its competitors. Featured photo by Artur Tumasjan on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 02, 2024 08:35 AM Eastern Standard Time

Image

World’s largest radiology AI marketplace CARPL raises $6m to accelerate the adoption of AI in clinical workflows

CARPL

As people live longer and as emphasis on early detection of disease increases, there is a mounting burden on the healthcare services industry globally. This is being especially felt in radiology teams who are witnessing an acute shortage of radiologists. Currently, there are over 200 companies building applications using AI to automate parts of the radiologists’ work to bridge this talent gap. Today CARPL, an enterprise imaging AI marketplace platform, is announcing a $6m funding round to enable healthcare providers to access, assess and integrate these radiology AI applications into their clinical workflows through a single user-interface, single data channel and single procurement system. The seed funding round was led by Stellaris Venture Partners, a leading enterprise software investor, with participation from strategic angel investors* from Novo Holdings, Leapfrog PE, Bain & Co, Boston Consulting Group, UnitedHealth Group among others. CARPL will use the fresh funds to expand the team in North America and continue to build its tech stack. With more than 700 US-FDA approved AI applications, healthcare providers grapple with navigating the complex landscape of niche AI solutions. The daunting task involves determining the best AI solution for them and their patients, then seamlessly integrating it in the radiologists' workflows. This complexity has resulted in the sluggish pace of AI adoption in healthcare. A recent joint statement by the world’s top radiology associations also brings to light the importance of validation, deployment and monitoring of AI while being used in clinical practice. CARPL’s technology platform addresses this need using its proprietary DEV-D framework allowing healthcare providers to first Discover (D), Explore (E) and Validate (V) AI applications from CARPL’s AI marketplace, and subsequently Deploy (D) the most appropriate application across their clinical workflows. CARPL stands out as the only platform in the market with deep AI validation and monitoring capabilities, thereby ensuring safe and seamless AI deployment while upholding patient-centricity at its core. Additionally, CARPL’s universal AI viewer serves as a single user interface for radiologists, enabling them to accept, reject or refine AI outputs, which can subsequently be used to improve the performance of the AI itself. Operational since 2021, CARPL was founded by Vidur Mahajan, a physician with an MBA from the Wharton School of Business who has spent more than 12 years in the diagnostics industry. CARPL’s leadership comprises Dr Vasanth Venugopal as Chief Medical Officer, Rohit Takhar as CTO and most recently Dhruv Sahai as COO. CARPL has also ramped up its advisory team with the appointment of Dr Vijay Rao, SVP of Enterprise Imaging at Jefferson Health and a past-President of the Radiology Society of North America. “Over the past two years, we have onboarded more than 50 AI developers having 100+ AI applications, which made us the largest AI marketplace in terms of number of AI applications offered to customers. We are proud that some of the largest healthcare enterprises in the world have vetted our technology and trust us to be their partner in their AI and automation journeys.” said Dr Vidur Mahajan, CEO of CARPL. Drawing parallels with the lab medicine industry, Vidur Mahajan added: “We are democratizing radiology in the same way that automation and robotics revolutionized lab medicine, where a single pathologist signs out thousands of tests each day. We envision a future where CARPL creates ‘super-radiologists’ - AI-enabled radiologists who are ten times more productive than traditional radiologists.” Vidur Mahajan brings deep domain expertise having previously grown revenue 10x to $20m in 10 years at his family business Mahajan Imaging, a leading radiology service provider. He conceptualized CARPL under the guidance of his father Dr Harsh Mahajan, a pioneer in radiology, while working on validation and deployment of AI at Mahajan Imaging. CARPL comprises a multidisciplinary team with clinicians, scientists, engineers and business experts, all working towards the singular goal of driving exponential health outcomes using the encapsulated value of the entire AI ecosystem with the ultimate aim of ensuring access of quality diagnostics to patients. CARPL has more than 120 papers and conference presentations to its credit, and has coined some seminal concepts in clinical AI such as algorithmic audits, clinical explainability failure and unboxing AI. CARPL’s technology platform is used by the world’s top healthcare organizations like the Singapore Government, Massachusetts General Hospital (Boston), Radiology Partners (Los Angeles), University Hospitals (Cleveland), I-MED Radiology (Australia), Albert Einstein Hospital (São Paulo), Clinton Health Access Initiative, to name a few. CARPL is also creating impact in the public health space by working with the Government of India to enable large scale Tuberculosis Screening Programmes in the most remote regions of the country. As the global disease burden increases, owing to aging populations, early detection of disease and an increase in chronic/lifestyle diseases, the need for radiology services will increase, which increases the need for AI-assistance and automation in the delivery of these services. The global healthcare AI market is expected to cross $170 billion by 2029, of which almost $20 billion will be in the domain of radiology. Today, of the about 700 AI-based applications which are approved by the US-FDA, 80% are related to radiology. This number is expected to grow exponentially as access to training data and computation power becomes cheaper and easier to access. Alok Goyal, Partner at Stellaris Venture Partners commented: “The volume of imaging scans show a steady 9% year-on-year growth, outpacing the growth in the number of radiologists at a mere 1.8%. Bridging this demand gap is a crucial challenge for healthcare providers, and we believe AI will be the key. CARPL's integrated platform, designed for testing, deploying, and monitoring radiology AI applications, is poised to empower healthcare providers by seamlessly integrating AI into their clinical workflows. We are thrilled to join forces with Vidur and his team on this transformative journey.” As it becomes easier to build AI, the number and nature of AI applications used by doctors to deliver healthcare will increase exponentially. A platform approach that builds on connecting these AI developers to healthcare providers is the only way to exponentially improve the access, affordability and quality of care delivered today. CARPL is a new layer in the healthcare CIO’s stack that enables seamless access to the entire AI and analytics ecosystem through a single integrated platform. About CARPL CARPL is democratizing access to high quality healthcare by connecting AI applications and healthcare providers, exponentially improving the access, affordability and quality of medical care. CARPL enterprise imaging AI platform provides a single user-interface, data channel and procurement system for healthcare providers to access, assess, integrate and buy radiology AI applications in a safe and seamless manner. CARPL was incubated at Mahajan Imaging & Labs, India’s largest radiology service provider, as its technology division focused on building scalable clinical tools for AI validation, deployment and monitoring, under the guidance of Dr Harsh Mahajan, a pioneer in the field of radiology. For more information please visit https://carpl.ai About Stellaris Venture Partners Stellaris is an early-stage tech-focused VC firm that partners with fearless founders who dream big, think differently, and have an unstoppable desire to challenge the status quo. The fund works with these teams at nascent stages to help transform their ideas into resilient businesses. Stellaris does so with a team of seasoned, diverse operators and entrepreneurs who bring significant experience in building businesses and by providing access to some of the most successful founders and professionals. Since its inception in 2017, Stellaris has backed many market leaders such as Mamaearth, Whatfix, Propelld, Turno, Rigi, and others. For more information on Stellaris Venture Partners, visit https://www.stellarisvp.com Contact Details CARPL Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://carpl.ai/

February 01, 2024 09:00 AM Eastern Standard Time

Image